MA46567A - Formes cristallines de l'éravacycline - Google Patents

Formes cristallines de l'éravacycline

Info

Publication number
MA46567A
MA46567A MA046567A MA46567A MA46567A MA 46567 A MA46567 A MA 46567A MA 046567 A MA046567 A MA 046567A MA 46567 A MA46567 A MA 46567A MA 46567 A MA46567 A MA 46567A
Authority
MA
Morocco
Prior art keywords
eravacycline
crystalline forms
crystalline
forms
eravacycline crystalline
Prior art date
Application number
MA046567A
Other languages
English (en)
Inventor
Chi-Li Chen
Minsheng He
Philip C Hogan
Danny Lafrance
Yansheng Liu
John Niu
Original Assignee
Tetraphase Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tetraphase Pharmaceuticals Inc filed Critical Tetraphase Pharmaceuticals Inc
Publication of MA46567A publication Critical patent/MA46567A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
MA046567A 2016-10-19 2017-10-19 Formes cristallines de l'éravacycline MA46567A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662410230P 2016-10-19 2016-10-19

Publications (1)

Publication Number Publication Date
MA46567A true MA46567A (fr) 2019-08-28

Family

ID=60263035

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046567A MA46567A (fr) 2016-10-19 2017-10-19 Formes cristallines de l'éravacycline

Country Status (15)

Country Link
US (4) US10961190B2 (fr)
EP (1) EP3529236B1 (fr)
JP (2) JP7492335B2 (fr)
KR (2) KR102880712B1 (fr)
CN (2) CN110582486B (fr)
DK (1) DK3529236T3 (fr)
ES (1) ES2978198T3 (fr)
HR (1) HRP20240605T1 (fr)
HU (1) HUE066360T2 (fr)
MA (1) MA46567A (fr)
PH (1) PH12019500822B1 (fr)
PL (1) PL3529236T3 (fr)
SG (1) SG11201903327PA (fr)
SI (1) SI3529236T1 (fr)
WO (1) WO2018075767A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031523B1 (ru) 2012-08-31 2019-01-31 Тетрафейз Фармасьютикалс, Инк. Тетрациклиновые соединения
US10975029B2 (en) 2016-01-22 2021-04-13 Sandoz Ag Crystalline eravacycline bis-hydrochloride
HRP20240605T1 (hr) * 2016-10-19 2024-07-19 Tetraphase Pharmaceuticals, Inc. Kristalni oblici eravaciklina
US12570604B2 (en) 2018-11-09 2026-03-10 Tetraphase Pharmaceuticals, Inc. Polymorphic forms of a tetracycline compound and uses thereof
CN119630403A (zh) * 2022-05-29 2025-03-14 本-古里安大学B.G.内盖夫技术和应用公司 用于治疗癌症的伊拉环素
CN115006411A (zh) * 2022-07-26 2022-09-06 中南大学湘雅医院 依拉环素类化合物的应用、药物及其制备方法

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB935384A (en) 1959-03-30 1963-08-28 Pfizer & Co C Tetracycline derivatives and preparation thereof
US3338963A (en) 1960-10-28 1967-08-29 American Cyanamid Co Tetracycline compounds
GB1034933A (en) 1962-10-29 1966-07-06 American Cyanamid Co 4-demethylamino-4-substituted amino 6-demethyl tetracyclines
US3364123A (en) 1963-05-06 1968-01-16 Squibb & Sons Inc Production of 4n-demethyl-4n-ethyl tetracyclines
USRE26253E (en) 1963-05-17 1967-08-15 And z-alkylamino-g-deoxytetracycline
GB1065715A (en) 1964-04-16 1967-04-19 Pfizer & Co C Tetracycline derivatives
US3247226A (en) 1964-07-06 1966-04-19 American Cyanamid Co 4-dimethylamino and 4-hydroxytetracycloxides
US3394178A (en) 1965-01-26 1968-07-23 Merck & Co Inc Nu-ethyloxytetracycline
GB1077598A (en) 1965-05-12 1967-08-02 Pfizer & Co C Preparation of n-demethyl tetracyclines
US3304227A (en) 1965-07-15 1967-02-14 Loyal E Loveless Antibiotic-containing animal feed
US3433709A (en) 1965-12-07 1969-03-18 American Cyanamid Co Biological transformation of alpha-6-deoxytetracyclines to tetracyclines
US3849493A (en) 1966-08-01 1974-11-19 Pfizer D-ring substituted 6-deoxytetracyclines
US3824285A (en) 1967-09-13 1974-07-16 Pfizer 4-oxo-4-dedimethylaminotetracycline-4,6-hemiketals
US3947517A (en) 1969-06-12 1976-03-30 Research Corporation Stereoselective introduction of tetracyclines hydroxyl group at 12(a) position in synthesis of tetracyclines
DE2437487A1 (de) 1974-08-03 1976-02-19 Merck Patent Gmbh 7-methoxy-6-thia-tetracycline und verfahren zu ihrer herstellung
DE2442829A1 (de) 1974-09-06 1976-03-18 Merck Patent Gmbh Tetracyclische verbindungen und verfahren zu ihrer herstellung
YU290176A (en) 1976-11-26 1982-05-31 Pliva Zagreb Process for preparing 4-dedimethylamino-4-arylsulfonamido-5a,6-anhydrotetracycline
US4666897A (en) 1983-12-29 1987-05-19 Research Foundation Of State University Inhibition of mammalian collagenolytic enzymes by tetracyclines
US4925833A (en) 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
USRE34656E (en) 1983-12-29 1994-07-05 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of bone deficiency
US4704383A (en) 1983-12-29 1987-11-03 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4935412A (en) 1983-12-29 1990-06-19 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US5308839A (en) 1989-12-04 1994-05-03 The Research Foundation Of State University Of New York Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
JP3016587B2 (ja) 1989-12-04 2000-03-06 ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク 非ステロイド抗炎症剤及びテトラサイクリンの配合
US5770588A (en) 1991-02-11 1998-06-23 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions of the prevention and treatment of root caries
US5231017A (en) 1991-05-17 1993-07-27 Solvay Enzymes, Inc. Process for producing ethanol
ES2168254T3 (es) 1991-10-04 2002-06-16 American Cyanamid Co Nuevas 7-sustituidas-9-(amino sustituido)-6-desmetil-6-desoxitetraciclinas.
USRE40183E1 (en) 1991-10-04 2008-03-25 Wyeth Holdings Corporation 7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
US5494903A (en) 1991-10-04 1996-02-27 American Cyanamid Company 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
US5258371A (en) 1992-05-29 1993-11-02 Kuraray Co., Ltd. Method to reduce connective tissue destruction
US6043225A (en) 1992-06-12 2000-03-28 Board Of Regents Of The University Of Washington Diagnosis and treatment of arterial chlamydial granuloma
US5284963A (en) 1992-08-13 1994-02-08 American Cyanamid Company Method of producing 7-(substituted)-9-[(substituted glycyl)-amidol]-6-demethyl-6-deoxytetra-cyclines
SG47520A1 (en) 1992-08-13 1998-04-17 American Cyanamid Co New method for the production of 9-amino-6-demethyl-6-deoxytetracycline
US5328902A (en) 1992-08-13 1994-07-12 American Cyanamid Co. 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
US5442059A (en) 1992-08-13 1995-08-15 American Cyanamid Company 9-[(substituted glycyl)amido)]-6-demethyl-6-deoxytetracyclines
US5420272A (en) 1992-08-13 1995-05-30 American Cyanamid Company 7-(substituted)-8-(substituted)-9-](substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
EP0599397B1 (fr) 1992-11-17 1996-08-28 The Research Foundation Of State University Of New York Tétracyclines comprenant les tétracyclines modifiées chimiquement afin d'être non-antimicrobiennes inhibent la réticulation excessive du collagène lors du diabète
US6043231A (en) 1993-03-02 2000-03-28 The Research Foundation Of State Univ. Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5523297A (en) 1993-03-02 1996-06-04 The Research Foundation Of State University Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5371076A (en) 1993-04-02 1994-12-06 American Cyanamid Company 9-[(substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines
US5668122A (en) 1993-07-28 1997-09-16 Fife; Rose S. Method to treat cancer with tetracyclines
AU1279095A (en) 1994-02-17 1995-09-04 Pfizer Inc. 9-(substituted amino)-alpha-6-deoxy-5-oxy tetracycline derivatives, their preparation and their use as antibiotics
US5574026A (en) 1994-12-13 1996-11-12 American Cyanamid Company Methods for inhibiting angiogenesis proliferation of endothelial or tumor cells and tumor growth
US5843925A (en) 1994-12-13 1998-12-01 American Cyanamid Company Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
US5834449A (en) 1996-06-13 1998-11-10 The Research Foundation Of State University Of New York Treatment of aortic and vascular aneurysms with tetracycline compounds
US5827840A (en) 1996-08-01 1998-10-27 The Research Foundation Of State University Of New York Promotion of wound healing by chemically-modified tetracyclines
US5789395A (en) 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5919774A (en) 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
US5837696A (en) 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
US5773430A (en) 1997-03-13 1998-06-30 Research Foundation Of State University Of New York Serine proteinase inhibitory activity by hydrophobic tetracycline
US5929055A (en) 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus
US20020123637A1 (en) 1998-01-23 2002-09-05 Stuart B. Levy Pharmaceutically active compounds and methods of use thereof
US6277061B1 (en) 1998-03-31 2001-08-21 The Research Foundation Of State University Of New York Method of inhibiting membrane-type matrix metalloproteinase
US6015804A (en) 1998-09-11 2000-01-18 The Research Foundation Of State University Of New York Method of using tetracycline compounds to enhance interleukin-10 production
US5977091A (en) 1998-09-21 1999-11-02 The Research Foundation Of State University Of New York Method of preventing acute lung injury
US5998390A (en) 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
CA2343038A1 (fr) 1998-09-28 2000-04-06 Maria Emanuel Ryan Nouvel inhibiteur de formation de cataracte
US6914057B1 (en) 1998-09-28 2005-07-05 The Research Foundation Of State University Of New York Inhibitor of cataract formation
US6231894B1 (en) 1999-10-21 2001-05-15 Duke University Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase
WO2001098260A1 (fr) 2000-06-16 2001-12-27 Trustees Of Tufts College Composes de phenyl tetracycline 7-n-substituee
CN1450989A (zh) 2000-07-07 2003-10-22 塔夫茨大学信托人 7－取代的四环素化合物
KR100674047B1 (ko) 2000-07-07 2007-01-25 트러스티즈 오브 터프츠 칼리지 9-치환된 미노사이클린 화합물
WO2002004404A2 (fr) 2000-07-07 2002-01-17 Trustees Of Tufts College Composes de tetracycline substitues en 7, 8 et 9
IL157860A0 (en) 2001-03-13 2004-03-28 Paratek Pharm Innc 7,9-substituted tetracycline compounds
CA2457234A1 (fr) 2001-03-14 2002-09-19 Mark L. Nelson Composes de tetracycline substitues, en tant qu'agents antifongiques
JP2005504722A (ja) 2001-03-14 2005-02-17 パラテック ファーマシューティカルズ インコーポレイテッド 相乗的抗真菌薬剤としての置換テトラサイクリン化合物
US8088820B2 (en) 2001-04-24 2012-01-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
CA2444899C (fr) 2001-04-24 2011-06-21 Paratek Pharmaceuticals, Inc. Composes de tetracycline substitues destines au traitement de la malaria
US20060194773A1 (en) 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
EP2332547A1 (fr) 2001-07-13 2011-06-15 Paratek Pharmaceuticals, Inc. Tetracyclines pour le traitement de la maladie inflammatoire des selles
EP2311798A1 (fr) 2002-01-08 2011-04-20 Paratek Pharmaceuticals, Inc. Composés de tétracycline 4-dedimethylamino
WO2003075857A2 (fr) 2002-03-08 2003-09-18 Paratek Pharmaceuticals, Inc. Composes a base de tetracycline a substitution aminomethyle
CA2479877C (fr) 2002-03-21 2012-08-21 Paratek Pharmaceuticals, Inc. Composes de tetracycline substituee
AU2003261161B2 (en) 2002-07-12 2009-09-10 Paratek Pharmaceuticals, Inc 3, 10, and 12a substituted tetracycline compounds
JP2006503898A (ja) 2002-10-24 2006-02-02 パラテック ファーマシューティカルズ， インク． マラリア治療のための置換テトラサイクリン化合物
EP1562608A4 (fr) 2002-10-24 2010-09-01 Paratek Pharm Innc Procedes d'utilisation de composes tetracycline substituee pour moduler l'arn
WO2005009943A2 (fr) 2003-07-09 2005-02-03 Paratek Pharmaceuticals, Inc. Composes de tetracycline substitues
WO2005082860A1 (fr) 2004-02-27 2005-09-09 National Research Council Of Canada Tetracyclines et leur utilisation en tant qu'inhibiteurs de la calpaine
ATE517885T1 (de) 2004-04-30 2011-08-15 Bayer Healthcare Llc Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs
EP1753713B1 (fr) 2004-05-21 2016-07-27 President and Fellows of Harvard College Synthese de tetracyclines et d'analogues de tetracyclines
EP2301916A3 (fr) 2004-10-25 2011-09-28 Paratek Pharmaceuticals, Inc. 4-aminotétracyclines et procédés d'utilisation associés
EP2269978A3 (fr) 2004-10-25 2011-09-21 Paratek Pharmaceuticals, Inc. Composés de tetracyclin substitués
CA2597212A1 (fr) 2005-02-04 2006-08-10 Paratek Pharmaceuticals, Inc. Derives 11a, 12 de composes de tetracycline
EP1848686A2 (fr) 2005-02-15 2007-10-31 Wyeth Tetracyclines 9-substituees
US20070093455A1 (en) 2005-07-21 2007-04-26 Paul Abato 10-substituted tetracyclines and methods of use thereof
EP2298324A1 (fr) 2006-01-24 2011-03-23 Paratek Pharmaceuticals, Inc. Procédé permettant d'augmenter la biodisponibilité orale de tetracyclines
EP2016044B1 (fr) 2006-04-07 2020-06-10 President and Fellows of Harvard College Dérivés de pentacycline pour le traitement d'infections
CA2652347A1 (fr) 2006-05-15 2007-11-22 Paratek Pharmaceuticals, Inc. Methodes de regulation de l'expression de genes ou de produits geniques a l'aide de composes de tetracycline substituee
US8440646B1 (en) 2006-10-11 2013-05-14 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of Bacillus anthracis infections
EP2479169B1 (fr) 2006-10-11 2014-12-03 President and Fellows of Harvard College Synthèse d'un intermédiaire de l'énone
IL270446B2 (en) 2006-12-21 2023-10-01 Paratek Pharm Innc A tetracycline compound, a pharmaceutical preparation containing the tetracycline compound, and the tetracycline compound or the pharmaceutical preparation for the treatment of the tetracycline-responsive condition
JP2010523684A (ja) 2007-04-12 2010-07-15 パラテック ファーマシューティカルズ インコーポレイテッド テトラサイクリン化合物を用いる、脊髄筋委縮症を治療するための方法
EA201070233A1 (ru) 2007-07-06 2010-08-30 Паратек Фармасьютикалс, Инк. Способы синтеза замещённых соединений тетрациклина (варианты)
US7939513B2 (en) 2007-09-07 2011-05-10 Dr. Reddy's Laboratories Limited Tetracycline derivatives as antibacterial agents
JP2011517697A (ja) 2008-04-14 2011-06-16 パラテック ファーマシューティカルズ インコーポレイテッド 置換テトラサイクリン化合物
TW202332671A (zh) * 2008-05-19 2023-08-16 美商Ｐｒｔｋ Ｓｐｖ２公司 四環素化合物之甲苯磺酸鹽及同素異形體
EP2307027A4 (fr) 2008-07-11 2012-08-15 Neumedics Dérivés de tétracycline présentant une activité antibiotique réduite et des bénéfices neuroprotecteurs
CN105367440A (zh) 2008-08-08 2016-03-02 四相制药公司 C7-氟取代的四环素化合物
EP2424834B1 (fr) 2009-04-30 2018-07-11 President and Fellows of Harvard College Synthèse de tétracyclines et intermédiaires de celles-ci
ES2440000T3 (es) 2009-05-08 2014-01-27 Tetraphase Pharmaceuticals, Inc. Compuestos de 8-aza-tetraciclina
CN102459153A (zh) 2009-05-08 2012-05-16 四相制药公司 四环素类化合物
US20120115819A1 (en) 2009-05-13 2012-05-10 Clark Roger B Pentacycline Compounds
HUE037852T2 (hu) 2009-08-28 2018-09-28 Tetraphase Pharmaceuticals Inc Tetraciklin-vegyületek
WO2011109899A1 (fr) 2010-03-10 2011-09-15 University Health Network Utilisation de la tigécycline pour le traitement du cancer
PL2552890T3 (pl) 2010-03-31 2017-07-31 Tetraphase Pharmaceuticals, Inc. Policykliczne związki tetracyklinowe
AR082633A1 (es) 2010-08-12 2012-12-19 Tetraphase Pharmaceuticals Inc Analogos de tetraciclina
WO2012047907A1 (fr) 2010-10-04 2012-04-12 President And Fellows Of Harvard College Synthèse de tétracyclines substituées en c5, leurs utilisations, et intermédiaires dans la synthèse de celles-ci
EP3574908B8 (fr) 2011-05-12 2024-09-11 Almirall LLC Composition pharmaceutique pour adminstration par voie orale comprenant des sels cristallins d'amide de l'acide (4s,4as,5ar,12as)-4-diméthylamino- 3,10,12,12a-tétrahydroxy-7-[(méthoxy(méthyl)amino)-méthyl]- 1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphtacène-2-carboxylique
EA031523B1 (ru) 2012-08-31 2019-01-31 Тетрафейз Фармасьютикалс, Инк. Тетрациклиновые соединения
MA40836A (fr) * 2014-10-23 2017-08-29 Tetraphase Pharmaceuticals Inc Procédures de semi-synthèse
WO2017097891A1 (fr) * 2015-12-10 2017-06-15 Sandoz Ag Éravacycline cristalline
US10975029B2 (en) 2016-01-22 2021-04-13 Sandoz Ag Crystalline eravacycline bis-hydrochloride
JP7184756B6 (ja) 2016-08-30 2022-12-20 テトラフェース ファーマシューティカルズ，インコーポレイテッド テトラサイクリン化合物および処置方法
HRP20240605T1 (hr) 2016-10-19 2024-07-19 Tetraphase Pharmaceuticals, Inc. Kristalni oblici eravaciklina

Also Published As

Publication number Publication date
PL3529236T4 (pl) 2024-07-08
HRP20240605T1 (hr) 2024-07-19
CN117903083A (zh) 2024-04-19
JP7598913B2 (ja) 2024-12-12
ES2978198T3 (es) 2024-09-06
CN110582486A (zh) 2019-12-17
JP7492335B2 (ja) 2024-05-29
JP2019531321A (ja) 2019-10-31
KR20240058958A (ko) 2024-05-07
PL3529236T3 (pl) 2024-07-08
KR102880712B1 (ko) 2025-11-03
SG11201903327PA (en) 2019-05-30
PH12019500822A1 (en) 2019-08-19
US20260055070A1 (en) 2026-02-26
US20230416212A1 (en) 2023-12-28
CN110582486B (zh) 2024-01-12
HUE066360T2 (hu) 2024-07-28
US12269807B2 (en) 2025-04-08
KR102660864B1 (ko) 2024-04-25
PH12019500822B1 (en) 2024-02-21
JP2022186979A (ja) 2022-12-15
KR20190065414A (ko) 2019-06-11
US11578044B2 (en) 2023-02-14
EP3529236B1 (fr) 2024-02-07
DK3529236T3 (da) 2024-05-13
SI3529236T1 (sl) 2024-08-30
US20190256462A1 (en) 2019-08-22
US20210363103A1 (en) 2021-11-25
US10961190B2 (en) 2021-03-30
WO2018075767A1 (fr) 2018-04-26
EP3529236A1 (fr) 2019-08-28

Similar Documents

Publication Publication Date Title
EP3464313A4 (fr) Nucléotides modifiés 5 '-cyclo-phosphonate
EP3430731A4 (fr) Architecture d'iugw
MA51819A (fr) Nouvelles formes cristallines
EP3544492A4 (fr) Gestionnaire de protocoles d'imagerie
EP3488670A4 (fr) Technologies d'architecture de bâti
ES1243880Y (es) Cepillo de dientes
EP3443293A4 (fr) Capteurs d'effort
PT4039675T (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
MA46567A (fr) Formes cristallines de l'éravacycline
EP3338142A4 (fr) Agents de développement d'encre
EP3379317A4 (fr) Lentille d'imagerie
EP3337485A4 (fr) Formes cristallines d'ibrutinib
EP3378606A4 (fr) Combinaison d'assistance
DK3829402T3 (da) Tæppe
EP3390422A4 (fr) Formes cristallines de lnt
EP3431808A4 (fr) Butée d'arrêt
EP3898809C0 (fr) Composition de polypropylène
EP3338446A4 (fr) Projections d'image
EP3444345A4 (fr) Dérivé d'arnmicro-143
EP2986597A4 (fr) Fluorescence réglable à l'aide de lieurs clivables
PT3419979T (pt) Compostos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
EP3297632A4 (fr) Clairance de galantamine d'amyloides
MA46266A (fr) Formes cristallines
MA48944A (fr) Forme cristalline de n-butyldéoxygalactonojirimycine
EP3426675A4 (fr) Formes salines cristallines